Veraxa Biotech (VRXA) Registration filing summary

Company overview and business model

• Oncology-focused biotech developing antibody therapies, with a clinical AML program and proprietary Click Chemistry ADC and BiTAC platforms for ADCs and T-cell engagers.

• Strategy centers on selective dual-targeting to improve tumor targeting and reduce toxicity; development combines internal programs with partnerships and potential out-licensing.

• Pipeline includes four BiTAC-TCE programs and two bispecific ADCs; VXA-901 and HER2 ADC programs are available for partnering or out-licensing.

• VXA-102 entered formal preclinical development in early 2026; the stated goal is up to three proprietary clinical-stage programs by 2029, subject to development success and regulatory clearance.

• R&D operates through a wholly owned Heidelberg subsidiary; 46 employees were reported as of July 15, 2026.

Financial performance and metrics

• FY2025 revenue was CHF 23,426 versus nil in FY2024; gross profit was CHF 15,461 after CHF 7,965 cost of goods sold.

• FY2025 net loss was CHF 66.6m versus CHF 28.1m in FY2024; operating loss was CHF 66.2m versus CHF 28.9m.

• FY2025 R&D expense rose to CHF 10.3m from CHF 6.3m; G&A increased to CHF 46.9m from CHF 17.1m, driven mainly by stock-based compensation.

• At Dec. 31, 2025, unrestricted cash was CHF 1.6m, net working capital deficit CHF 3.7m, and accumulated deficit CHF 98.5m; operating cash use was CHF 9.9m for FY2025.

• Pro forma combined FY2025 net loss was CHF 159.8m, including a CHF 89.3m IFRS 2 listing-services expense; capitalization included CHF 25.4m total indebtedness.

Use of proceeds and capital allocation

• No proceeds go to the issuer from Lincoln Park’s resale; up to $50m gross may be received from issuer share sales to Lincoln Park over 24 months, if elected and conditions are met.

• Intended uses of net proceeds are R&D, marketing activities, and general working capital; management retains broad discretion and may reprioritize spending.

• Capital needs include advancing platforms and candidates, preclinical and clinical work, regulatory submissions, manufacturing, IP protection, and future commercialization capabilities.